TGFβ2 CRISPR/Cas9 KO Plasmid (m): sc-423367
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- TGFβ2 CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the TGFβ2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: TGFβ2 Antibody (H-6): sc-374659
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
TGFβ2 CRISPR/Cas9 KO Plasmid (m) | sc-423367 | 20 µg | $397.00 |
Overview
Tgfb2 encodes transforming growth factor beta 2 (TGFβ2), a secreted cytokine that signals through TGFβ receptors to activate SMAD2/3-dependent transcriptional programs and crosstalk with non-canonical pathways including MAPK, PI3K/AKT, and Rho GTPases. In mouse tissues, TGFβ2 contributes to regulation of extracellular matrix deposition, cell proliferation and differentiation, epithelial–mesenchymal transition, and immune modulation within the tissue microenvironment. Dysregulated TGFβ2 signaling is linked to aberrant fibrosis, altered angiogenesis, and changes in inflammatory tone, with relevance to developmental abnormalities and tumor biology. Because pathway outputs are highly context dependent, Tgfb2 is frequently studied to dissect how local TGFβ cues shape cell fate and stromal remodeling.
TGFβ2 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Tgfb2 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Tgfb2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Tgfb2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish TGFβ2 protein expression.
This CRISPR knockout system enables efficient generation of Tgfb2-deficient cell models for investigation of TGFβ2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Tgfb2 exon(s) critical for TGFβ2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Tgfb2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by TGFβ2 CRISPR/Cas9 KO Plasmid (m) and TGFβ2 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Tgfb2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by TGFβ2 HDR Plasmid (m) and TGFβ2 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Tgfb2 homology arms to support homology-directed repair at defined Tgfb2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.